Bharat Biotech expands into advanced biologics with Nucelion Therapeutics, a new CRDMO for cell and gene therapy ...

Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene therapies. This new enti ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Bharat Biotech launches Nucelion Therapeutics, a CRDMO focused on advanced cell and gene therapies for global life science innovators.

Bharat Biotech launches Nucelion Therapeutics, a CRDMO in Hyderabad for advanced cell and gene therapy manufacturing and development.

Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, ...

Bharat Biotech launches Nucelion, the next-gen cell and gene therapy, CRDMO: Our Bureau, Bengaluru Monday, November 3, 2025, 17:30 Hrs [IST] Nucelion Therapeutics, a newly establi ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership ...

Hyderabad: Bharat Biotech International Ltd has announced the formal launch of Nucelion Therapeutics Pvt Ltd, marking its ...